This information is intended only for healthcare professionals resident in the Great Britain

Prescribing Information (PI) for Xeljanz® (tofacitinib) Great Britain (GB) and Northern Ireland (NI) and Maxtrex (methotrexate) United Kingdom (UK)​​​

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

Great Britain

  • Xeljanz (tofacitinib) 5mg film-coated tablets - PI for GB
  • Xeljanz (tofacitinib) 11mg prolonged release tablets - PI for GB
  • Xeljanz (tofacitinib) 10mg film-coated tablets - PI for GB
  • Xeljanz (tofacitinib) 1mg/ml oral solution - PI for GB

Northern Ireland

  • Xeljanz (tofacitinib) 5mg and 10mg film-coated tablets - PI for NI
  • Xeljanz (tofacitinib) 11mg prolonged release tablets - PI for NI
  • Xeljanz (tofacitinib) 1mg/ml oral solution - PI for NI

United Kingdom

  • Maxtrex (methotrexate) 2.5mg tablets – PI for UK

Xeljanz (tofacitinib) 5mg film-coated tablets - PI for GB

Xeljanz (tofacitinib) 11mg prolonged release tablets - PI for GB

Xeljanz (tofacitinib) 10mg film-coated tablets - PI for GB

Xeljanz (tofacitinib) 1mg/ml Oral Solution - PI for GB

Xeljanz (tofacitinib) 5mg and 10mg film-coated tablets - PI for NI

Xeljanz (tofacitinib) 11mg prolonged release tablets - PI for NI

Xeljanz (tofacitinib) 1mg/ml Oral Solution - PI for NI

Maxtrex (methotrexate) 2.5mg tablets – PI for UK

PP-XEL-GBR-4598. May 2023